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Overwhelming infection causes significant morbidity and mortality among patients 
treated with bone marrow transplantation (BMT) for primary immune deficiencies, 
syndromes of bone marrow failure, or cancer. The polymorphonuclear leukocyte (PMN; 
neutrophil) is the first responder to microbial invasion and acts within the innate immune 
system to contain and clear infections. PMNs contain, and possibly clear, infections 
in part by forming neutrophil extracellular traps (NETs). NETs are extensive lattices of 
extracellular DNA and decondensed chromatin decorated with antimicrobial proteins 
and degradative enzymes, such as histones, myeloperoxidase, and neutrophil elastase. 
They trap and contain microbes, including bacteria and fungi, and may directly affect 
extracellular microbial killing. Whether or not deficient NET formation contributes to the 
increased risk for overwhelming infection in patients undergoing BMT remains incom-
pletely characterized, especially in the pediatric population. We examined NET formation 
in  vitro in PMNs isolated from 24 patients who had undergone BMT for 13 different 
clinical indications. For these 24 study participants, the median age was 7 years. For 6 
of the 24 patients, we examined NET formation by PMNs isolated from serial, peripheral 
blood samples drawn at three different clinical time points: pre-BMT, pre-engraftment, 
and post-engraftment. We found decreased NET formation by PMNs isolated from 
patients prior to BMT and during the pre-engraftment and post-engraftment phases, 
with decreased NET formation compared with healthy control PMNs detected even out 
to 199 days after their BMT. This decrease in NET formation after BMT did not result 
from neutrophil developmental immaturity as we demonstrated that >80% of the PMNs 
tested using flow cytometry expressed both CD10 and CD16 as markers of terminal 
differentiation along the neutrophilic lineage. These pilot study results mandate further 
exploration regarding the mechanisms or factors regulating NET formation by PMNs in 
patients at risk for overwhelming infection following BMT.
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inTrODUcTiOn
The polymorphonuclear leukocyte (PMN; neutrophil) is the first 
circulating leukocyte to respond to tissue damage or infection 
and the primary effector cell of innate immunity and acute 
inflammation (1, 2). PMNs rapidly infiltrate areas of injury or 
infection where they participate in wound healing, infection 
containment, and microbial killing. Disorders associated with 
a deficiency or impairment of neutrophil number or function, 
such as neutropenia, chronic granulomatous disease (CGD), or 
leukocyte adhesion deficiency syndrome, predispose to severe 
bacterial and fungal infections (3) and are associated with sig-
nificant morbidity and mortality (1). Novel neutrophil activities 
continue to be elucidated suggesting that PMNs influence all 
aspects of immunity (2).
Recently, neutrophils isolated from healthy adult donors 
were shown to undergo programed cell death distinct from 
apoptosis and necrosis to form neutrophil extracellular traps 
(NETs) (4, 5). NETs are extensive lattices of extracellular DNA 
and decondensed chromatin decorated with antimicrobial 
proteins and degradative enzymes, such as myeloperoxidase 
and neutrophil elastase (NE). NETs affect extracellular killing 
of bacteria and fungi (6–9). We recently identified impaired 
NET formation as a novel innate immune deficiency in human 
newborn infants (10). PMNs isolated from the umbilical cord 
blood of newborn infants, whether born at term or prematurely, 
demonstrate impaired NET formation and extracellular bacte-
rial killing in the first week of life as compared with PMNs 
isolated from healthy adults (10, 11). Thus, severe, early onset, 
neonatal infections may be associated with deficient PMN NET 
formation leading to impaired extracellular microbial contain-
ment and killing.
Pediatric and adult patients undergoing bone marrow trans-
plant (BMT) also exhibit an increased risk for severe infection. 
A 2006 study found that 85% of cord blood transplant recipi-
ents and 69% of hematopoietic stem cell transplant recipients 
developed at least one severe infection within a 3-year median 
follow-up time (12). Such infections accounted for 59 and 
61% of infection-related mortality for cord blood and periph-
eral blood stem cell transplant recipients, respectively (12). 
Posttransplant immune reconstitution is thought to mirror 
neonatal immune development, and the complicated process 
of immune system reconstitution continues over 1–2  years 
(13). However, the risk for microbial infection is greatest in 
the pre-engraftment period when patients are neutropenic 
(14). A previous study concluded that an unknown element 
of neutrophil dysfunction exists in patients after BMT which 
contributes to the high risk for infection (15). In addition, a 
recent report looked at NET formation following BMT in 
12 adult patients and demonstrated a significant decrease in 
NET formation compared with healthy adult controls (16). We 
hypothesized that this increased risk for infection results, in 
part, from deficient NET formation by neutrophils produced 
by the nascent, peri-engraftment immune system and tested 
this hypothesis in a primarily pediatric population. We now 
show that NET formation by PMNs isolated from pediatric and 
adult patients before and after BMT exhibit diminished NET 
formation in vitro and that this failure of NET formation is not 
simply the result of neutrophil immaturity.
MaTerials anD MeThODs
PMn isolation
Polymorphonuclear leukocytes were isolated from EDTA anti-
coagulated venous blood of 24 participants either undergoing 
BMT or after completion of BMT using a research protocol 
approved by the IRB at the University of Utah. Fourteen of the 
participants were <18 years old at the time of BMT (Table 1), and 
the median age for our study participants was 7 years. Eighteen 
of our study participants only had NET formation assessed 
after engraftment following BMT. Four of these participants 
had only qualitative assessment of NET formation using live 
cell imaging, while the additional 14 of these participants had 
NET formation assessed both qualitatively and quantitatively. 
For 6 of the 24 participants, we obtained serial, peripheral blood 
samples at three different time points: pre-BMT (n = 3), pre-
engraftment (n = 6), and post-engraftment (n = 6) (Table 1). 
For all experiments, we performed assays of NET formation 
and granulocytic differentiation markers in parallel using 
PMNs isolated from the peripheral blood of healthy adults as 
positive controls for NET formation and PMN differentiation 
(10, 11, 17). In all, we collected peripheral blood from 24 adult 
donors as controls for the experiments outlined. These adult 
donors are described as healthy, fasting, medication free, and 
non-hospitalized, consenting control subjects aged ≥21  years 
who donate peripheral blood routinely under a University of 
Utah IRB approved protocol. No attempt was made to match 
control donors to study participants with regard to age, sex, 
or ethnicity. PMN suspensions (>96% pure) were prepared by 
positive immunoselection using anti-CD15-coated microbeads 
and an auto-MACS cell sorter (Miltenyi Biotec, Inc.) and were 
resuspended at 2 ×  106  cells/mL concentration in serum-free 
M-199 media warmed at 37°C.
live cell imaging of neT Formation
Qualitative assessment of NET formation was performed, as 
previously referenced (10, 17). Briefly, participant primary 
PMNs were incubated with control buffer or stimulated with LPS 
(100 ng/mL) for 2 h at 37°C in 5% CO2/95% air on glass coverslips 
coated with poly-l-lysine. After stimulation, PMNs were gently 
washed with PBS and incubated with a mixture of cell permeable 
(Syto Green, Molecular Probes) and impermeable (Sytox Orange, 
Molecular Probes) DNA fluorescent dyes. Confocal microscopy 
was accomplished using a FV300 1X81 Microscope and the 
FluoView software (Olympus). Both 20× and 60× objectives 
were used. Z-series images were obtained at a step size of 1 μm 
over a range of 20 μm for each field. The Olympus FluoView 
software and the Adobe Photoshop CS2 software were used for 
image processing. Semiquantitative analysis of NET formation 
was accomplished using the ImageJ analysis software (NIH) 
and a standardized grid system with rigorous NET quantitation. 
TaBle 1 | Patient characteristics according to age group.
age group (years)
characteristics, n(%) combined 0–10 11–30 (≥31)
n 24 15 (62.5%) 6 (25%) 3 (12.5%)
gender
Female 12 (50%) 9 (60%) 1 (17%) 2 (67%)
Male 12 (50%) 6 (40%) 5 (83%) 1 (33%)
Primary disease
SCID 2 (8%) 2 (13%) 0 (0%) 0 (0%)
Relapsed ALL 6 (25%) 4 (27%) 2 (33%) 0 (0%)
Bilineal leukemia 2 (8%) 2 (13%) 0 (0%) 0 (0%)
Relapsed AML 1 (4%) 1 (7%) 0 (0%) 0 (0%)
Neuroblastoma 3 (13%) 3 (20%) 0 (0%) 0 (0%)
AML 3 (13%) 0 (0%) 2 (33%) 1 (33%)
MDS 1 (4%) 0 (0%) 0 (0%) 1 (33%)
AML/MDS 1 (4%) 1 (7%) 0 (0%) 0 (0%)
ALL 1 (4%) 0 (0%) 1 (17%) 0 (0%)
CLL 1 (4%) 0 (0%) 0 (0%) 1 (33%)
Hodgkins lymphoma 1 (4%) 0 (0%) 1 (17%) 0 (0%)
Anaplastic ependymoma 1 (4%) 1 (7%) 0 (0%) 0 (0%)
Aplastic anemia 1 (4%) 1 (7%) 0 (0%) 0 (0%)
hla
Matched, unrelated 10 (42%) 4 (27%) 4 (67%) 2 (67%)
PTD of PMN engraftment, mean 20.4 25.3 17.5 16.5
Matched, related 4 (17%) 3 (20%) 0 (0%) 1 (33%)
PTD of PMN engraftment, mean 23 25 – 17
Cord blood 5 (21%) 4 (27%) 1 (17%) 0 (0%)
PTD of PMN engraftment, mean 20.2 16.8 34 –
Autologous 5 (21%) 4 (27%) 1 (17%) 0 (0%)
PTD of PMN engraftment, mean 11 10.8 12 –
survival (as of October 2014)
Alive 16 (67%) 10 (67%) 3 (50%) 3 (100%)
Dead 8 (33%) 5 (33%) 3 (50%) 0 (0%)
PTD, posttransplant day.
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Statistical comparisons were made via one way ANOVA with 
Tukey’s multiple comparisons post hoc testing.
Quantitation of neT 
Formation – supernatant  
histone h3 content
We determined supernatant total histone H3 content as a sur-
rogate for NET formation, as previously referenced (17). After 
live cell imaging of control and stimulated primary PMNs 
(2 × 106 cells/mL; LPS 100 ng/mL), the cells were incubated with 
new media containing DNase (40  U/mL) for 15  min at room 
temperature to break down and release NETs formed in response 
to stimulation. The supernatant was gently removed and centri-
fuged at 420×  g for 5  min. The cell-free supernatant was then 
mixed 3:1 with 4× Laemmli buffer prior to Western blotting. 
We used a polyclonal primary antibody against human histone 
H3 protein (Cell Signaling Technology) and infrared secondary 
antibodies (Li-Cor Biosciences). Imaging and densitometry were 
performed on the Odyssey™ infrared imaging system (Li-Cor 
Biosciences). Statistical comparisons were made via one way 
ANOVA with post hoc testing.
assessment of PMn Differentiation
We assessed PMN differentiation through analysis of CD16 
and CD10 protein surface expression on PMNs isolated from 
BMT patients using flow cytometry, as previously described 
(18). PMNs were isolated by positive immunoselection using 
anti-CD15-coated microbeads and an auto-MACS cell sorter 
(Miltenyi Biotec, Inc.) as described (10, 17, 18) and prepared 
for flow cytometry using FACS lysis buffer (Becton-Dickinson). 
PMN CD16 and CD10 cell surface protein expression was 
determined by incubating directly conjugated antibodies against 
human CD 16 (PE; 10 μL/test) and human CD10- (FITC; 10 μL/
test) or isotype-matched control antibodies in the dark at 4°C for 
30 min (All antibodies from Becton-Dickinson). FACS analysis 
was accomplished in the University of Utah Flow Cytometry 
Core using a Becton-Dickinson FACS Scan Analyzer and Flow-Jo 
analysis software (Version 9.7.6).
resUlTs
In this study, we assessed in vitro NET formation in response to 
LPS stimulation by PMNs isolated from 24 BMT patients with 
varying ages at and indications for BMT (Table 1). In 18 of these 
BMT patients, we were only able to assess post-engraftment 
NET formation (posttransplant day range: 14–199). For six BMT 
patients, however, we assessed peri-engraftment NET formation 
at the time of BMT, collecting pre-BMT, pre-engraftment, and 
post-engraftment PMN samples for analysis of NET formation. 
All six of these patients had received chemotherapy for malignan-
cies prior to pre-BMT conditioning. Chemotherapeutic agents 
used for these patients included busulfan, carboplatin, etoposide, 
cyclophosphamide, daunorubicin, vincristine, cytarabine, and 
mitoxantrone. We did not obtain pre-BMT neutrophil samples 
from the two patients in this cohort undergoing BMT for severe 
combined immunodeficiency syndrome and, therefore, did not 
have pre-BMT chemotherapy. Consistent with a previous report 
(16), we demonstrated a significant decrease in NET formation by 
PMNs isolated both pre- and post-engraftment following BMT in 
response to LPS stimulation as compared with healthy adult con-
trol PMNs (Figures 1B–D). Furthermore, using semiquantitative 
image analysis, we demonstrated a statistically significant decrease 
in NET formation by LPS-stimulated PMNs isolated from study 
participants prior to BMT (Figure  1B). While our histone H3 
release assay results did not show a correlative statistically sig-
nificant decrease in NET formation by LPS-stimulated pre-BMT 
PMNs compared with healthy control PMNs (Figure  1C), an 
apparent trend toward decreased NET formation was detected 
(Figure 1C); this correlates with the qualitative and semiquanti-
tative image analysis results (Figures 1A,B).
Of the PMNs isolated post-engraftment from 18 BMT patients, 
NET formation following LPS stimulation, while detectable, was 
decreased compared with healthy control PMNs (Figures 1A–C). 
Furthermore, a subset of patients analyzed showed decreased 
NET formation despite being 60–199 days removed from their 
BMT (not shown). This suggests that decreased NET formation 
may be an unrecognized aspect of PMN dysfunction after BMT 
that contributes to the prolonged risk for severe infection seen in 
these patients, which may last up to 3 years (13).
FigUre 1 | PMns isolated from patients at BMT demonstrate decreased neT formation following in vitro stimulation with lPs. We assessed NET 
formation by LPS-stimulated PMNs isolated from patients undergoing bone marrow transplant (n = 3 pre-BMT, n = 6 pre-engraftment, n = 19 post-engraftment) 
compared with control LPS-stimulated PMNs isolated from healthy adult donors. PMNs were stimulated with LPS (100 ng/mL; 1 h) and NET formation was 
determined qualitatively and quantitatively using (a) live cell imaging (60× magnification), (B) semiquantitative image analysis, and (c,D) release of histone H3 (fold 
change over baseline; mean ± SEM). (a) NET-associated, extracellular DNA is shown in red fluorescence (yellow arrows). Nuclear DNA is shown in green 
fluorescence. (B) We analyzed NET formation in a semiquantitative manner using ImageJ analysis software and a standardized grid system for all captured live cell 
imaging results (20× magnification, n > 6 images analyzed per patient group). The y-axis depicts the number of times that NETs crossed the standardized grid lines 
(**p < 0.01 and ***p < 0.001). We employed a one way ANOVA statistical tool with Tukey’s post hoc testing. (c) NET-associated histone H3 release is shown as fold 
change over baseline on the y-axis (*p < 0.05 and **p < 0.01) compared with baseline (red dashed line), arbitrarily set at 1. We employed a one way ANOVA 
statistical tool with Tukey’s post hoc testing. (D) Here, we reanalyze the NET-associated histone H3 release data for only these study participants from whom serial 
PMN samples were obtained (n = 3 pre-BMT, n = 6 pre-engraftment, n = 6 post-engraftment, and n = 11 controls). NET-associated histone H3 release is again 
shown as for (c) *p < 0.05 compared with baseline (red dashed line), arbitrarily set at 1. We employed a one way ANOVA statistical tool with Dunn’s post hoc 
testing.
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One possible cause for this prolonged NET deficiency  following 
BMT is that a large proportion of neutrophils isolated pre-
engraftment and right after engraftment may be developmental 
precursors of fully differentiated PMNs. Therefore, we assessed 
surface expression of the protein markers of PMN differentiation 
CD16 and CD10 by PMNs isolated from three BMT patients at 
the pre-BMT, pre-engraftment, and post-engraftment stages. 
Surface expression of CD16 and CD10 denotes differentiation 
of granulocytic precursors into fully differentiated, segmented 
PMNs (19). We found no differences in PMN differentiation 
between pre-BMT, pre-engraftment, and post-engraftment 
PMNs, and the PMN preparations from all three groups showed 
that >80% of the isolated PMNs expressed both CD16 and CD10 
(Figure 2).
DiscUssiOn
This brief report demonstrates that NET formation by PMNs 
isolated from both pediatric and adult patients following BMT 
is impaired in response to LPS stimulation and that this does not 
result from incomplete differentiation of the PMNs  circulating 
in these patients. These findings extend the literature as a con-
firmatory report of decreased NET formation in adult patients 
following BMT and are the first to show this potential immune 
deficiency following BMT in pediatric patients. A recent report 
by Domingo-Gonzalez et al. demonstrated a similar decrease 
in NET formation by PMNs isolated from BMT patients (16). 
Their study characterized phorbol-12-mystirate (PMA)-
induced NET formation by PMNs isolated from 12 patients 
undergoing BMT for indications, including various cancers 
and myelodysplastic disorders. These patients were all adults 
and the median participant age in their study was 59  years. 
In contrast, while we did include five adult patients in our 
study cohort, the median age for our study participants was 
7  years. Another difference between our studies was the use 
of different agonists to induce NET formation. While PMA is 
a known, non-physiologic PMN stimulatory agonist and does 
induce NET formation (5), our use of LPS for NET induction 
more closely approximates the in vivo triggering by infectious 
agents.
FigUre 2 | Fully differentiated and segmented PMns circulate in cancer patients before and after bone marrow transplantation. (a) We assessed the 
differentiation of circulating PMNs in three patients undergoing BMT using flow cytometry. Different peripheral blood samples were obtained pre-BMT, after BMT but 
pre-engraftment, and after engraftment (ANC > 500). Surface expression of CD16 and CD10, two protein markers expressed by fully differentiated PMNs, was 
determined, and the percentage of PMNs expressing both CD16 and CD10 is shown on the y-axis for all three groups of isolated PMNs. No statistically significant 
differences were noted. (B) Representative scatter plot results obtained using flow cytometry are shown with surface CD16 PE expression on the y-axis, and surface 
CD10 FITC expression seen on the x-axis. The percentage of PMNs expressing both CD16 and CD10 is shown in the top right corner of each scatter plot.
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Our results are particularly pertinent given the pronounced 
predisposition of BMT patients, both adult and pediatric, to 
severe infections, especially in the pre-engraftment period 
(13, 20). We acknowledge the low sample size for these investi-
gations as a weakness of this pilot study, but note that this study 
is the largest to date to specifically examine NET formation after 
BMT in humans and the only one to examine NET formation 
before human BMT. An additional, potential weakness of this 
study is the failure to control for age by using age-matched 
controls in our assays of NET formation. While this represents a 
potential confounder in this study, we note that age-specific nor-
mal values for NET formation in both pediatric and adult popu-
lations have not been determined. To date, non-disease specific 
abnormalities in NET formation have only been characterized 
in the very young (10, 11) and very old (21). Another study 
weakness is our inability to examine the effects of autologous 
versus allogenic bone marrow reconstitution on NET formation 
following BMT. This very important question will be addressed 
by planned future studies where a larger number of autologous 
and allogenic BMT patients can be enrolled. In addition, we also 
point to the diversity in indications for and times after BMT 
as strengths of this report suggestive that deficiencies of NET 
formation in these patients may contribute to their increased 
risk for severe infection (20). Bacterial and fungal infections 
continue to cause significant morbidity and mortality in the 
pretransplantation, pre-engraftment, and post-engraftment 
periods, which together last through 100 days after BMT (13). 
While controversy exists regarding the extent of their direct 
antimicrobial activity, NETs clearly trap bacteria and fungi 
(22). This effect alone can lead to containment and clearance 
of an infectious agent, a finding confirmed in a murine model 
of necrotizing fasciitis with NET inhibition in PAD4 knockout 
mice (23). Correlative data in the human system also suggest a 
role for NET formation in clearance of microbes during severe 
infection. Bianchi et  al. reported the use of gene therapy to 
restore NET formation and to control refractory pulmonary 
aspergillosis in a patient with CGD (8, 9). These studies and our 
results suggest a need to examine NET formation prospectively 
in a larger cohort of BMT patients where the number, types 
(bacterial, fungal, and parasitic), and severity of infections may 
be correlated with indications for BMT, pre-BMT chemothera-
peutic regimens, and aspects of neutrophil function in addition 
to NET formation.
Clearly, further studies are warranted to determine the mecha-
nisms or factors leading to this deficit in NET formation after 
BMT. We have previously shown NET formation to be deficient 
in undifferentiated HL-60 leukocytes, a cancer cell line arrested in 
the pro-myelocytic stage of PMN differentiation (17). However, 
retinoic acid-induced differentiation of HL-60 leukocytes leads 
to robust NET formation in these leukocytes in response to 
LPS stimulation (17). These findings led to our initial hypoth-
esis regarding the mechanism for decreased NET formation 
following BMT. With this study, we have disproven our initial 
hypothesis that decreased NET formation by PMNs isolated 
after BMT results from neutrophil developmental immaturity, 
a finding that might also have been expected given our results 
in PMNs isolated from newborn infant cord blood (10). In their 
recently published paper, Domingo-Gonzalez et al. also studied 
PMNs isolated from a murine model of BMT and demonstrated 
that increased levels of prostaglandin E2 (PGE2) in mice following 
BMT inhibited PMA-induced NET formation (16). This finding 
is also consistent with the results of Shishikura et al. who showed 
that PGE2 inhibits NET formation by PMA-induced murine and 
human PMNs through increased production of cyclic AMP (24). 
Together, these reports elucidate yet another regulatory pathway 
governing NET formation in human and murine PMNs. Our 
report, in contrast, focused on PMNs isolated from human BMT 
patients or healthy controls and examined only one possible rea-
son for decreased NET formation – that of decreased myeloid cell 
maturity after BMT. Still, future studies in PMNs isolated from 
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BMT patients, both before and after BMT, will need to include 
interrogation of the many known molecular pathways governing 
NETosis. Examples of such studies would include an examination 
of the toll-like receptor signaling pathways; an investigation of 
BMT effects on intracellular reactive oxygen species generation 
(5) and autophagy (25), with the BMT effects on the role of NE/
myeloperoxidase in triggering NETosis in these patients as well 
(26); and finally an assessment of PAD4 activity as an enzyme 
leading to nuclear decondensation, a precursor step toward 
NETosis (23, 27).
Finally, our findings suggest that PMNs isolated from BMT 
patients prior to BMT may exhibit a deficit in NET formation 
and mandate that NET formation be studied in PMNs isolated 
from other immunodeficiency patients as well as cancer patients 
in general. If confirmed, NET deficiency by pre-BMT PMNs 
may be a result of the specific disorders leading up to BMT or 
from chemotherapy prior to BMT. To date, the effects of cancer 
chemotherapeutic agents on NET formation by neutrophils have 
not been extensively studied. Our study examining the role of the 
mammalian target of rapamycin (mTOR) signaling pathway in 
the regulation of NET formation did investigate rapamycin, an 
immunosuppressant and chemotherapeutic agent used in solid 
organ transplantation and some cancer treatment regimens, as 
an inhibitor of NET formation. We found that rapamycin inhib-
ited NET formation in an mTOR and hypoxia-inducible factor 
1-dependent manner. None of the participants in this report were 
exposed to rapamycin, and none of the chemotherapeutic agents 
to which they were exposed have been studied with regard to 
their effects on NET formation. Clearly, with these findings and 
the findings of Domingo-Gonzalez et al., further investigation is 
warranted (16). Alternatively, the question of a circulating inhibi-
tor of NET formation should be considered, with PGE2 being a 
leading candidate. Identification of an endogenous inhibitor of 
NET formation might prove important given the newly described 
pathogenic role of dysregulated NET formation in syndromes of 
pathologic inflammation (28, 29).
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